AU2018347527B2 - Compositions and methods for treatment of fibrosis - Google Patents

Compositions and methods for treatment of fibrosis Download PDF

Info

Publication number
AU2018347527B2
AU2018347527B2 AU2018347527A AU2018347527A AU2018347527B2 AU 2018347527 B2 AU2018347527 B2 AU 2018347527B2 AU 2018347527 A AU2018347527 A AU 2018347527A AU 2018347527 A AU2018347527 A AU 2018347527A AU 2018347527 B2 AU2018347527 B2 AU 2018347527B2
Authority
AU
Australia
Prior art keywords
liposome
composition
fibrosis
liver
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018347527A
Other languages
English (en)
Other versions
AU2018347527A1 (en
Inventor
Adam ELHOFY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bast Biotechnology
Original Assignee
Bast Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bast Biotechnology filed Critical Bast Biotechnology
Publication of AU2018347527A1 publication Critical patent/AU2018347527A1/en
Application granted granted Critical
Publication of AU2018347527B2 publication Critical patent/AU2018347527B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018347527A 2017-10-11 2018-10-11 Compositions and methods for treatment of fibrosis Active AU2018347527B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570847P 2017-10-11 2017-10-11
US62/570,847 2017-10-11
PCT/US2018/055521 WO2019075277A1 (en) 2017-10-11 2018-10-11 COMPOSITIONS AND METHODS FOR TREATING FIBROSIS

Publications (2)

Publication Number Publication Date
AU2018347527A1 AU2018347527A1 (en) 2020-04-23
AU2018347527B2 true AU2018347527B2 (en) 2024-08-15

Family

ID=66101109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018347527A Active AU2018347527B2 (en) 2017-10-11 2018-10-11 Compositions and methods for treatment of fibrosis

Country Status (11)

Country Link
US (1) US12544394B2 (https=)
EP (1) EP3694517A4 (https=)
JP (1) JP7379348B2 (https=)
KR (1) KR20200068692A (https=)
CN (1) CN111278441A (https=)
AU (1) AU2018347527B2 (https=)
CA (1) CA3084359A1 (https=)
IL (1) IL273850B1 (https=)
MX (1) MX2020003718A (https=)
SG (1) SG11202003300WA (https=)
WO (1) WO2019075277A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY210343A (en) * 2020-06-04 2025-09-12 Hovid Berhad Composition for normalisation of fatty liver and method for producing the same
EP4274566A4 (en) * 2021-01-06 2024-10-30 The Trustees of Indiana University TOCOTRIENOL COMPOSITIONS AND METHODS FOR TREATING NONALCOHOLIC STEATOHEPATITIS
CN112587649A (zh) * 2021-01-19 2021-04-02 中日友好医院(中日友好临床医学研究所) 一种三肽化合物及其铜离子螯合物在预防和治疗矽肺中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1171047A (en) * 1915-11-10 1916-02-08 John Hornagy Car-door fastener.
US2282236A (en) * 1940-06-19 1942-05-05 Bay State Optical Co Eyeglass construction
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5284835A (en) * 1992-07-31 1994-02-08 Lieber Charles S Use of dilinoleoylphosphatidylcholine (DLPC) for treatment and prevention of cirrhosis and fibrosis in the liver
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
CA2181390C (en) * 1995-07-18 2001-04-24 Pankaj Modi Phospholipid formulations
WO1997006784A1 (en) 1995-08-15 1997-02-27 Universite Libre De Bruxelles Liposomes preparation method and plant
CA2282236A1 (en) * 1998-11-06 2000-05-06 Peter Stys The use of excitatory amino acid transporter inhibitors to protect against cns white matter injury
US20040146516A1 (en) * 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
CN1518987A (zh) * 2000-06-02 2004-08-11 大连万友贸易有限公司 多聚不饱和磷脂酰胆碱的新用途
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US20080107723A1 (en) * 2006-09-28 2008-05-08 Perkins Walter R Methods of Treating Pulmonary Distress
JP5080779B2 (ja) 2006-10-25 2012-11-21 テルモ株式会社 リポソーム製剤の製造方法
WO2011009119A2 (en) 2009-07-17 2011-01-20 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating fibrotic disorders
CA3102008A1 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US20160015656A2 (en) * 2010-08-05 2016-01-21 Nitto Denko Corporation Composition for regenerating normal tissue from fibrotic tissue
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102631330B (zh) * 2012-04-19 2013-05-29 海南美大制药有限公司 一种兰索拉唑囊泡型磷脂凝胶缓释固体制剂
HK1207977A1 (en) * 2012-04-25 2016-02-19 Trustees Of Tufts College Silk microspheres and methods for surface lubrication
EP2874605A1 (en) 2012-07-18 2015-05-27 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
KR20160125352A (ko) * 2013-12-20 2016-10-31 이센셜 파마수티컬스 엘엘씨 세포 배양용 배지
CN103816118A (zh) * 2014-02-14 2014-05-28 西藏海思科药业集团股份有限公司 一种多烯磷脂酰胆碱注射用组合物及其制备方法
KR20170107256A (ko) 2016-03-15 2017-09-25 이진희 미백 화장료 조성물
CN105997854B (zh) * 2016-06-14 2018-11-27 成都天台山制药有限公司 多烯磷脂酰胆碱注射液组合物和制法
CN106310220A (zh) 2016-08-17 2017-01-11 浙江中医药大学 一种包封鳖甲肽的rgd‑ssl脂质体及其制备方法

Also Published As

Publication number Publication date
US20200246361A1 (en) 2020-08-06
IL273850B1 (en) 2026-01-01
EP3694517A4 (en) 2021-07-14
CN111278441A (zh) 2020-06-12
IL273850A (en) 2020-05-31
AU2018347527A1 (en) 2020-04-23
JP2021502404A (ja) 2021-01-28
KR20200068692A (ko) 2020-06-15
WO2019075277A1 (en) 2019-04-18
EP3694517A1 (en) 2020-08-19
US12544394B2 (en) 2026-02-10
CA3084359A1 (en) 2019-04-18
BR112020007083A2 (pt) 2020-09-24
MX2020003718A (es) 2020-10-05
SG11202003300WA (en) 2020-05-28
JP7379348B2 (ja) 2023-11-14

Similar Documents

Publication Publication Date Title
US20140037715A1 (en) Disulfiram formulation and uses thereof
AU2018347527B2 (en) Compositions and methods for treatment of fibrosis
JP6568577B2 (ja) 肝内胆汁うっ滞症の治療
US10668028B2 (en) Methods and use of inducing apoptosis in cancer cells
CA2641308A1 (en) Use of phosphatases to treat tumors overexpressing n-cor
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
CN102573831A (zh) 用于治疗免疫相关病症的去铁胺-金属络合物
JP2025131596A (ja) 血液障害及び／又は関連疾患を治療する、又は予防するための１５－ｈｅｐｅを含む組成物
US20230181759A1 (en) Compositions for treatment of viral respiratory infections and methods of use thereof
AU2008331500B2 (en) Intravesical compositions with valrubicin for the treatment of bladder cancer
KR20210148078A (ko) 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
US20160220581A1 (en) Chromium compositions for the treatment or prevention of diabetic retinopathy
US20130005824A1 (en) Treatment of ischemic tissue
Sahebkar et al. Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia
BR112020007083B1 (pt) Composições compreendendo fosfatidilcolina e derivados de fosfatidilcolina
US20230240991A1 (en) Proteophospholiposomes having hdl-type vesicles
US20160310460A1 (en) Itch suppression by fucoxanthin
JP2026509094A (ja) 尿毒症性掻痒の治療
KR20190039735A (ko) 주사비의 치료 또는 예방을 위한 조성물 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)